Mohammad Ali Esmaili1, Ahmad Kazemi1, Farhad Zaker1, Mohammad Faranoush2,3, Mohammad Reza Rezvany1,2,4. 1. Department of Hematology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran . 2. Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran . 3. Mahak Hematology Oncology Research Center (MAHAK-HORC), Mahak Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm 17176, Sweden.
Abstract
BACKGROUND: The current study aims to investigate the relationship of miR-24 expression with plasma methotrexate (MTX) levels, therapy-related toxicities, and event-free survival (EFS) in Iranian pediatric acute lymphoblastic leukemia (ALL) patients. METHODS: The study included 74 ALL patients in consolidation phase and 41 healthy children. RNA was extracted from plasma, polyadenylated, and reverse transcribed. miR-24 expression was determined by quantitative polymerase chain reaction (qPCR). Plasma MTX concentrations were measured by high performance liquid chromatography (HPLC) 48 h after high-dose methotrexate (HD-MTX) injection. The diagnosis of ALL was further subclassified as B-ALL or T-ALL via flow cytometry. RESULTS: miR-24 expression was less in pediatric ALL patients than in the control group (p = 0.0038). Furthermore, downregulation of miR-24 was correlated with intermediate- to high-grade HD-MTX therapy toxicities (p = 0.025). Nevertheless, no statistically significant associations were seen between miR-24 levels and plasma MTX levels 48 h after HD-MTX administration (p > 0.05) or EFS in pediatric ALL patients (p > 0.05). CONCLUSION: miR-24 expression may contribute to interindividual variability in response to intermediate- to highgrade HD-MTX therapy toxicities under Berlin Frankfurt Munster (BFM) treatment.
BACKGROUND: The current study aims to investigate the relationship of miR-24 expression with plasma methotrexate (MTX) levels, therapy-related toxicities, and event-free survival (EFS) in Iranian pediatric acute lymphoblastic leukemia (ALL) patients. METHODS: The study included 74 ALL patients in consolidation phase and 41 healthy children. RNA was extracted from plasma, polyadenylated, and reverse transcribed. miR-24 expression was determined by quantitative polymerase chain reaction (qPCR). Plasma MTX concentrations were measured by high performance liquid chromatography (HPLC) 48 h after high-dose methotrexate (HD-MTX) injection. The diagnosis of ALL was further subclassified as B-ALL or T-ALL via flow cytometry. RESULTS: miR-24 expression was less in pediatric ALL patients than in the control group (p = 0.0038). Furthermore, downregulation of miR-24 was correlated with intermediate- to high-grade HD-MTX therapy toxicities (p = 0.025). Nevertheless, no statistically significant associations were seen between miR-24 levels and plasma MTX levels 48 h after HD-MTX administration (p > 0.05) or EFS in pediatric ALL patients (p > 0.05). CONCLUSION: miR-24 expression may contribute to interindividual variability in response to intermediate- to highgrade HD-MTX therapy toxicities under Berlin Frankfurt Munster (BFM) treatment.
Authors: Jaqueline C de Oliveira; María Sol Brassesco; Carlos Alberto Scrideli; Luiz Gonzaga Tone; Aru Narendran Journal: Pediatr Blood Cancer Date: 2012-04-10 Impact factor: 3.167
Authors: Ye Yuan; Joost Kluiver; Jasper Koerts; Debora de Jong; Bea Rutgers; F Reeny Abdul Razak; Martijn Terpstra; Boudewijn E Plaat; Ilja M Nolte; Arjan Diepstra; Lydia Visser; Klaas Kok; Anke van den Berg Journal: Am J Pathol Date: 2017-04-20 Impact factor: 4.307
Authors: Prasun J Mishra; Rita Humeniuk; Pravin J Mishra; Giuseppe S A Longo-Sorbello; Debabrata Banerjee; Joseph R Bertino Journal: Proc Natl Acad Sci U S A Date: 2007-08-08 Impact factor: 11.205
Authors: Julia Oldenburg; Maria Fürhacker; Christina Hartmann; Philipp Steinbichl; Rojin Banaderakhshan; Alexander Haslberger Journal: Environ Epigenet Date: 2021-11-25